A study to characterize the safety, efficacy, pharmacokinetics of subcutaneous administration of Etentamig (ABBV-383) in patients with relapsed or refractory Multiple Myeloma
Фаза 1 – тестване на безопасността при малка група хора
Заболявания:
Relapsed or Refractory Multiple Myeloma (R/R MM)
Спонсор: AbbVie Deutschland GmbH & Co. KG
Налично на:
БГ
Обобщение
Trial status: Authorised
Кой може да участва
Age group: 18-64 years, 65+ years
Gender: Female, Male
Target enrollment: 30 participants
БГ
EN